Abstract:BACKGROUND:Oral vaccine is highly desired for infectious disease which is caused by pathogens infection through the mucosal surface. The design of suitable vaccine delivery system is ongoing for the antigen protection from the harsh gastric environment and target to the Peyer's patches to induce sufficient mucosal immune responses. Among various potential delivery systems, bacterial inclusion bodies have been widely used as delivery systems in the field of nanobiomedicine. However, a large number of heterologous complex proteins could be difficult to propagate in E. coli and fusion partners are often used to enhance target protein expression. As a safety concern the fusion protein need to be removed from the target protein to get tag-free protein, especially for the production of protein antigen in vaccinology. Until now, there is no report on how to remove fusion tag from inclusion body particles in vitro and in vivo. Coxsackievirus B3 (CVB3) is a leading causative agent of viral myocarditis and orally protein vaccine is high desired for CVB3-induced myocarditis. In this context, we explored a tag-free VP1 inclusion body nanoparticles production protocol though a truncated Ssp DnaX mini-intein spontaneous C-cleavage in vivo and also exploited the VP1 inclusion bodies as an oral protein nanoparticle vaccine to protect mice against CVB3-induced myocarditis.RESULTS:We successfully produced the tag-free VP1 inclusion body nanoparticle antigen of CVB3 and orally administrated to mice. The results showed that the tag-free VP1 inclusion body nanoparticles as an effective antigen delivery system targeting to the Peyer's patches had the capacity to induce mucosal immunity as well as to efficiently protect mice from CVB3 induce myocarditis without any adjuvant. Then, we proposed the use of VP1 inclusion body nanoparticles as good candidate for oral vaccine to against CVB3-induced myocarditis.CONCLUSIONS:Our tag-free inclusion body nanoparticles production procedure is easy and low cost and may have universal applicability to produce a variety of tag-free inclusion body nanoparticles for oral vaccine.

Enhanced Resistance to Coxsackievirus B3-Induced Myocarditis by Intranasal Co-Immunization of Lymphotactin Gene Encapsulated in Chitosan Particle

Enhancement of the mucosal immune responses and prophylactic effect of a novel coxsackievirus B3-specific mucosal DNA vaccine by co-administration of lymphotactin

Mucosal Immunization with High-Mobility Group Box 1 in Chitosan Enhances DNA Vaccine-Induced Protection Against Coxsackievirus B3-Induced Myocarditis

Intranasal delivery of chitosan-DNA vaccine generates mucosal SIgA and anti-CVB3 protection.

Mechanism of Enhanced Viral-Myocarditis-prophylactic Effect of a Novel Coxsackievirus B3 Mucosal Vaccine by LTN Adjuvant

Modulation of Immunogenicity and Immunoprotection of Mucosal Vaccine Against Coxsackievirus B3 by Optimizing the Coadministration Mode of Lymphotactin Adjuvant

Prophylaxis of CVB3-induced Myocarditis by Intranasal Immunization with Chitosan-pcDNA3-VP1 Vaccine

Intranasal Gene Immunization with Chitosan-DNA Vaccine Generates Mucosal IgA and Protects BALB/C Mice Against CVB3 Challenge

Mucosal co-immunization with AIM2 enhances protective SIgA response and increases prophylactic efficacy of chitosan-DNA vaccine against coxsackievirus B3-induced myocarditis.

[A Novel DNA Vaccine Containing Endosome-Fusogenic Peptide Prevents CVB3-induced Myocarditis in Mice].

Incorporation of a Bi-Functional Protein FimH Enhances the Immunoprotection of Chitosan-Pvp1 Vaccine Against Coxsackievirus B3-induced Myocarditis.

M Cell-Targeting Strategy Facilitates Mucosal Immune Response and Enhances Protection Against CVB3-induced Viral Myocarditis Elicited by Chitosan-Dna Vaccine.

AIM2 Co-Immunization Favors Specific Multifunctional CD8+ T Cell Induction and Ameliorates Coxsackievirus B3-induced Chronic Myocarditis

An intranasal attenuated Coxsackievirus B3 vaccine induces strong systemic and mucosal immunity against CVB3 lethal challenge

An Albumin-Binding Domain Peptide Confers Enhanced Immunoprotection Against Viral Myocarditis By Cvb3 Vp1 Vaccine

Generation of protective immune responses against coxsackievirus B3 challenge by DNA prime-protein boost vaccination.

A Vesicular Stomatitis Virus-Based Mucosal Vaccine Promotes Dendritic Cell Maturation and Elicits Preferable Immune Response Against Coxsackievirus B3 Induced Viral Myocarditis

[Protective immunoresponse to CVB3 induced by gene immunization with pcDNA3-VP1].

In Vivo Delivery Approaches Influence Immune Responses Induced by Chitosan-Dna Vaccination

Intein-Mediated Backbone Cyclization of Vp1 Protein Enhanced Protection of Cvb3-Induced Viral Myocarditis

Spontaneous C-cleavage of a Truncated Intein As Fusion Tag to Produce Tag-Free VP1 Inclusion Body Nanoparticle Vaccine Against CVB3-induced Viral Myocarditis by the Oral Route.